Evidence map›Paper›PMID 32664511›Full record

ArticleDiagnostics (Basel, Switzerland)2020

Evaluation of Commercial qPCR Kits for Detection of SARS-CoV-2 in Pooled Samples.

Vlad Petrovan, Virgil Vrajmasu, Ana Cristina Bucur, Dan Sebastian Soare, Eugen Radu, Paula Dimon, Mihaela Zaulet

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vlad PetrovanThe Pirbright Institute, Woking, Surrey GU24 0NF, UK.
Virgil VrajmasuVetWork Diagnostix, 820166 Tulcea, Romania.ORCID 0000-0002-1299-9590
Ana Cristina BucurEmergency Hospital Bucharest, Molecular Pathology Laboratory, 050098 Bucharest, Romania.
Dan Sebastian SoareEmergency Hospital Bucharest, Molecular Pathology Laboratory, 050098 Bucharest, Romania.
Eugen RaduEmergency Hospital Bucharest, Molecular Pathology Laboratory, 050098 Bucharest, Romania.
Paula DimonPersonal Genetics, 010987 Bucharest, Romania.
Mihaela ZauletDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the current pandemic, a global shortage of reagents has drawn interest in developing alternatives to increase the number of coronavirus tests. One such alternative is sample pooling. We compared commercial kits that are used in COVID-19 diagnostics in terms of their sensitivity and feasibility for use in pooling. In this preliminary study, we showed that pooling of up to 80 samples did not affect the efficacy of the kits. Additionally, the RNA-dependent RNA polymerase (RdRp) gene is a more suitable target in pooled samples than the envelope (E) gene. This approach could provide an easy method of screening a large number of samples and help adjust different governmental regulations.

Indexed as

diagnosticsPCRpooling strategySARS-CoV-2

Identifiers

PMID32664511
PMCPMC7400658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.